Detail page

Knowledge Web

Person

Joachim Havla (1981-)

Arzt

Name	Joachim Havla
Time	1981- (Date of birth and death)
Place	Pegnitz (Geburtsort) Deutschland
Academic degree	PD Dr. med.
Profession	Arzt (characteristic profession) Neurologe
Variant	Joachim Bernhard Havla
Further information	Diss. Universität München, Medizinische Fakultät; Institute of Clinical Neuroimmunology, Ludwig- Maximilians University, Munich
Record type	Person
GND-Identifier	141343583
Record ID	141343583
Involved in show all Cognition in patients with neuromyelitis optica spectrum disorders : A prospective multicentre study of 217 patients (CogniNMO-Study) Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis : A Multicenter Cohort Study Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study) Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study) Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision Prognostic models in multiple sclerosis: progress and challenges in clinical integration Framework for personalized prediction of treatment response in relapsing-remitting multiple sclerosis: a replication study in independent data Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management Association between retinal thickness and disease characteristics in adult epilepsy: a cross‐sectional OCT evaluation Different pain phenotypes are associated with anti-Caspr2 autoantibodies NMOSD IgG Impact Retinal Cells in Murine Retinal Explants Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis MOG-IgG-Associated Bilateral Optic Neuritis in Temporal Relation to Monkeypox Vaccination Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis Therapy challenges for NMOSD in a patient with HIV Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD) Structured Reporting in Multiple Sclerosis – Consensus-Based Reporting Templates for Magnetic Resonance Imaging of the Brain and Spinal Cord Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria Structured reporting in multiple sclerosis – consensus-based reporting templates for magnetic resonance imaging of the brain and spinal cord DNP - Der Neurologe & Psychiater 2021;22(5):48-59 NMOSD - vom ersten Schub zur optimalen Behandlung First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies Optical Coherence Tomography to Assess Neurodegeneration in Phenylalanine Hydroxylase Deficiency Pain, depression, and quality of life in adults with MOG-antibody–associated disease TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants Retinal axonal degeneration in Niemann–Pick type C disease Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study Managing Risks with Immune Therapies in Multiple Sclerosis Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis Biomarker der Inflammation und Neurodegeneration zur Diagnostik und individuellen Therapie entzündlicher ZNS-Erkrankungen Risks and risk management in modern multiple sclerosis immunotherapeutic treatment Apheresis therapies for NMOSD attacks : a retrospective study of 207 therapeutic interventions Apheresis therapies for NMOSD attacks : a retrospective study of 207 therapeutic interventions Apheresis therapies for NMOSD attacks A retrospective study of 207 therapeutic interventions Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response Influence of female sex and fertile age on neuromyelitis optica spectrum disorders Influence of female sex and fertile age on neuromyelitis optica spectrum disorders Patient-to-patient transmission of natalizumab-associated PML? Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab ``infusion group'' Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate Humane Chondrozyten und Lymphozyten als Modell zur Untersuchung der Toxizität von Matrixmaterialien für die Gewebezüchtung Humane Chondrozyten und Lymphozyten als Modell zur Untersuchung der Toxizität von Matrixmaterialien für die Gewebezüchtung

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Joachim Havla (1981-)

Cognition in patients with neuromyelitis optica spectrum disorders : A prospective multicentre study of 217 patients (CogniNMO-Study)

Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis : A Multicenter Cohort Study

Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)

Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)

Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision

Prognostic models in multiple sclerosis: progress and challenges in clinical integration

Framework for personalized prediction of treatment response in relapsing-remitting multiple sclerosis: a replication study in independent data

Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis

Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Association between retinal thickness and disease characteristics in adult epilepsy: a cross‐sectional OCT evaluation

Different pain phenotypes are associated with anti-Caspr2 autoantibodies

NMOSD IgG Impact Retinal Cells in Murine Retinal Explants

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study

Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis

Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis

MOG-IgG-Associated Bilateral Optic Neuritis in Temporal Relation to Monkeypox Vaccination

Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis

Therapy challenges for NMOSD in a patient with HIV

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)

Structured Reporting in Multiple Sclerosis – Consensus-Based Reporting Templates for Magnetic Resonance Imaging of the Brain and Spinal Cord

Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair

Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode

Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria

Structured reporting in multiple sclerosis – consensus-based reporting templates for magnetic resonance imaging of the brain and spinal cord

DNP - Der Neurologe & Psychiater 2021;22(5):48-59

NMOSD - vom ersten Schub zur optimalen Behandlung

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine

Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?

Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies

Optical Coherence Tomography to Assess Neurodegeneration in Phenylalanine Hydroxylase Deficiency

Pain, depression, and quality of life in adults with MOG-antibody–associated disease

TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy

Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants

Retinal axonal degeneration in Niemann–Pick type C disease

Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study

Managing Risks with Immune Therapies in Multiple Sclerosis

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis

Biomarker der Inflammation und Neurodegeneration zur Diagnostik und individuellen Therapie entzündlicher ZNS-Erkrankungen

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment

Apheresis therapies for NMOSD attacks : a retrospective study of 207 therapeutic interventions

Apheresis therapies for NMOSD attacks : a retrospective study of 207 therapeutic interventions

Apheresis therapies for NMOSD attacks A retrospective study of 207 therapeutic interventions

Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis

Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study

No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders

Patient-to-patient transmission of natalizumab-associated PML?

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod

Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab ``infusion group''

Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate

Humane Chondrozyten und Lymphozyten als Modell zur Untersuchung der Toxizität von Matrixmaterialien für die Gewebezüchtung

Humane Chondrozyten und Lymphozyten als Modell zur Untersuchung der Toxizität von Matrixmaterialien für die Gewebezüchtung